Free tool
FAERS Monitor: Synalar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 012787 or its brand name (Synalar, Fluocinolone Acetonide). Reports on generic versions are filed under their own applications.
Reports
1,919
Serious
865
45% of reports
Hospitalization
333
Death reported
53
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus191
- drug ineffective182
- rash152
- diarrhoea120
- off label use113
- fatigue103
- psoriasis102
- headache97
- pain97
- nausea88
- dermatitis atopic81
- product use in unapproved indication78
- dry skin74
- product dose omission issue74
- arthralgia71
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 18 |
| 2006 | 7 |
| 2007 | 13 |
| 2008 | 11 |
| 2009 | 18 |
| 2010 | 20 |
| 2011 | 32 |
| 2012 | 34 |
| 2013 | 28 |
| 2014 | 30 |
| 2015 | 59 |
| 2016 | 93 |
| 2017 | 85 |
| 2018 | 95 |
| 2019 | 130 |
| 2020 | 137 |
| 2021 | 139 |
| 2022 | 168 |
| 2023 | 194 |
| 2024 | 185 |
| 2025 | 223 |
| 2026 | 191 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,240 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dermatitis atopicSignal | 81 | 16.9 | 13.6 | 1,194 |
| psoriasisSignal | 102 | 8.6 | 7.1 | 678 |
| dry skinSignal | 74 | 6.1 | 4.9 | 311 |
| pruritusSignal | 191 | 5.4 | 4.8 | 702 |
| rashSignal | 152 | 3.8 | 3.3 | 321 |
| product use in unapproved indicationSignal | 78 | 3.5 | 2.8 | 135 |
| product dose omission issueSignal | 74 | 2.8 | 2.2 | 82 |
| diarrhoeaSignal | 120 | 2.0 | 1.7 | 64 |
| arthralgia | 71 | 1.9 | 1.5 | 29 |
| pain | 97 | 1.7 | 1.4 | 30 |
| headache | 97 | 1.7 | 1.4 | 28 |
| drug ineffective | 182 | 1.5 | 1.3 | 33 |
| fatigue | 103 | 1.5 | 1.2 | 14 |
| off label use | 113 | 1.4 | 1.2 | 14 |
| nausea | 88 | 1.2 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.